Clinical Trial Update: Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF) [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of XXB750 in heart failure patients with reduced or mildly reduced ejection fraction has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Mildly Reduced Ejection Fraction
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• XXB750

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF) | Phase 1 | Status: COMPLETED